Les stents à élution de médicaments : preuves, incertitudes et pratiques

Low Cycle Fatigue Study of AISI 316L Cardiovascular Stent for Two Different Designs

“…However, due to the risk of bleeding, the first dose of drug is delayed depending on the patient condition, which may lead to the artery closure. This situation gave rise to the emergence of drug-eluting stents (DES), developed to prevent restenosis [6], by which the antiplatelet drug is released into blood to cease platelet coagulation in early hours of convalescence. However, concern has grown over their ability to resist deformation and fracture [7,8].…”

Élaboration de nouveaux systèmes biodégradables électrogreffables pour stents endovasculaires métalliques

“…ments : le stent métallique, la molécule pharmacologiquement active et son mode de délivrance constitué le plus souvent par un polymère [1][2][3][4][5][6]. Alors que les DES présents sur le marché utilisent des polymères biostables, de nouveaux polymères biodégradables ont été testés.…”

Short and Medium-Term Evaluation of Patients in Coronary Post-Angioplasty: Préliminary results at the Cardiology Department of the Hospital University Aristide Le Dantec of Dakar (Senegal): Study on 38 Cases

“…According to WHO, they are responsible for nearly 7 million deaths per year, or 12.8% of global mortality in 2012 [1]. Its management has seen spectacular advances with the advent of coronary angioplasty [3]. Continually relying on both technical and pharmacological improvements, it rapidly became a safe therapeutic whose indications are constantly expanding.…”